Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3232-3239

  Irvin Jr , William J ^a   Walko, Christine M ^a   Weck, Karen E ^a   Ibrahim, Joseph G ^a   Chiu, Wing K ^a   Dees, E Claire ^a   Moore, Susan G ^b   Olajide, Oludamilola A ^b   Graham, Mark L ^d   Canale, Sean T ^c   Raab, Rachel E ^e   Corso, Steven W ^h   Peppercorn, Jeffrey M ^f   Anderson, Steven M ^g   Friedman, Kenneth J ^g   Ogburn, Evan T ⁱ   Desta, Zeruesenay ⁱ   Flockhart, David A ⁱ   McLeod, Howard L ^a   Evans, James P ^a   Carey, Lisa A ^a   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Rex Hematology/Oncology Associates   (United States)

^c Carolina Breast Care Specialists   (United States)

^d Waverly Hematology Oncology   (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

^f DUKE UNIVERSITY   (United States)

^g LABORATORY CORPORATION OF AMERICA   (United States)

^h PA   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG METABOLISM; ENZYME ASSAY; ENZYME METABOLISM; FEASIBILITY STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEASIBILITY STUDIES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 80052020634     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.4427     Document Type: Article

References (52)

1. Surveillance, Epidemiology, and End Results: Cancer of the Breast, in Ries LAG, Melbert D, Krapcho M, et al (eds): SEER Stat Fact Sheets. Bethesda, MD, National Cancer Institute, 2008
2. Hoskins J.M., Carey L.A., McLeod H.L.: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576-586, 2009
3. Lien E.A., Solheim E., Kvinnsland S., et al: Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304-2308, 1988
4. Desta Z., Ward B.A., Soukhova N.V., et al: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075, 2004 (Pubitemid 39108928)
5. Goetz M.P., Rae J.M., Suman V.J., et al: Pharmacogenetics of tamoxifen biotransformation isassociated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
6. Lim Y.C., Desta Z., Flockhart D.A., et al: Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has antiestrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478, 2005 (Pubitemid 40568978)
7. Stearns V., Johnson M.D., Rae J.M., et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
8. Lim Y.C., Li L., Desta Z., et al: Endoxifen, a secondary metabolite of tamoxifen, and 4-OHtamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503-512, 2006 (Pubitemid 44061223)
9. Johnson M.D., Zuo H., Lee K.H., et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004 (Pubitemid 38987269)
10. Bradford L.D.: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243, 2002
11. Jin Y., Desta Z., Stearns V., et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
12. Dezentje V.O., Van Blijderveen N.J., Gelderblom H., et al: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429, 2010
13. Goetz M.P., Berry D.A., Klein TE: Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 33)
14. Okishiro M., Taguchi T., Jin Kim S., et al: Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115:952-961, 2009
15. Nowell S.A., Ahn J., Rae J.M., et al: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258, 2005 (Pubitemid 40903087)
16. Wegman P., Elingarami S., Carstensen J., et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7, 2007
17. Wegman P., Vainikka L., Stal O., et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290, 2005
18. Dezentje V.O., Van Schaik R.H., Vletter-Bogaatz J.M., et al: Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. J Clin Oncol 28:70s, 2010 (abstr 510)
19. Ramon y Cajal T., Altes A., Pare L., et al: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119:33-38, 2009
20. Bijl M.J., Van Schaik R.H., Lammers L.A., et al: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118:125- 130, 2009
21. Goetz M.P., Suman V., Ames M.M., et al: Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: Long-term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 6037)
22. Schroth W., Antoniadou L., Fritz P., et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007 (Pubitemid 350232249)
23. Kiyotani K., Mushiroda T., Sasa M., et al: Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99:995-999, 2008 (Pubitemid 351997603)
24. Gonzalez-Santiago S., Zárate R, Haba- Rodriguez J, et al: CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. J Clin Oncol 25:25s, 2007 (abstr 590)
25. Newman W.G., Hadfield K.D., Latif A., et al: Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14:5913-5918, 2008
26. Xu Y., Sun Y., Yao L., et al: Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423-1429, 2008
27. Goetz M.P., Knox S.K., Suman V.J., et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007 (Pubitemid 47555336)
28. Goetz M.P., Suman V.J., Couch F.J., et al: Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14:5864-5868, 2008
29. Kiyotani K., Mushiroda T., Imamura C.K., et al: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287-1293, 2010
30. Lim H.S., Ju Lee H., Seok Lee K., et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007
31. Thompson A., Quinlan P., Bray S., et al: CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy. Presented at the 2009 Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 35)
32. Schroth W., Goetz M.P., Hamann U., et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429- 1436, 2009
33. Aubert R.E., Stanek E.J., Yao J., et al: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27:9s, 2009 (suppl; abstr CRA508)
34. Kelly C.M., Juurlink D.N., Gomes T., et al: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 340:c693, 2010
35. Rae J.M., Drury S., Hayes D.F., et al: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S1-7)
36. Leyland-Jones B., Regan M.M., Bouzyk M., et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Presented at the San Antonio Breast Cancer Symposium Abstract, San Antonio, TX, December 8-12, 2010 (#S1-8)
37. Bratherton D.G., Brown C.H., Buchanan R., et al: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50:199-205, 1984 (Pubitemid 14061945)
38. Ward H.W.: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. BMJ 1:13-14, 1973
39. Fallowfield L.J., Leaity S.K., Howell A., et al: Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189-199, 1999 (Pubitemid 29389581)
40. Stanton A.L., Bernaards C.A., Ganz P.A.: The BCPT symptom scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97:448-456, 2005 (Pubitemid 40528608)
41. Noether G.E.: Sample size determination for some common nonparametric tests. J Am Stat Assoc 82:645-647, 1987
42. Stokes M.E., Davis C.S., Kock G.: Categorical Data Analysis Using the SAS System (ed 2). Cary, NC, SAS Institute Inc, 2000, pp 514-518
43. Stahl M., Wilke H., Schmoll H.J., et al: A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 3:167- 168, 1992
44. Kaiser-Kupfer M.I., Lippman M.E.: Tamoxifen retinopathy. Cancer Treat Rep 62:315-320, 1978 (Pubitemid 8335892)
45. Dowsett M., Haynes B.P.: Hormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255-263, 2003 (Pubitemid 37412564)
46. Carey L.A., Perou C.M., Livasy C.A., et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006 (Pubitemid 43854964)
47. Madlensky L., Flatt S.W., Natarajan L., et al: Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 6045)
48. Mortimer J.E., Flatt S.W., Parker B.A., et al: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421-426, 2008 (Pubitemid 351431079)
49. Peppercorn J., Hamilton E., Qiu S., et al: Practice and attitudes amond US oncologists towards CYP2D6 testing for patients on tamoxifen. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 1077)
50. Irvin W.J., Carey L.A., Olajide O., et al: Patients'understanding of a CYP2D6 tamoxifen genotyping study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 608)
51. Potter L., Oakley D., De Leon-Wong E., et al: Measuring compliance among oral contraceptive users. Fam Plann Perspect 28:154-158, 1996
52. Hershman D.L., Kushi L.H., Shao T., et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010